Matches in UGent Biblio for { <https://biblio.ugent.be/publication/5822272#aggregation> ?p ?o. }
Showing items 1 to 36 of
36
with 100 items per page.
- aggregation classification "A1".
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2014".
- aggregation format "application/pdf".
- aggregation hasFormat 5822272.bibtex.
- aggregation hasFormat 5822272.csv.
- aggregation hasFormat 5822272.dc.
- aggregation hasFormat 5822272.didl.
- aggregation hasFormat 5822272.doc.
- aggregation hasFormat 5822272.json.
- aggregation hasFormat 5822272.mets.
- aggregation hasFormat 5822272.mods.
- aggregation hasFormat 5822272.rdf.
- aggregation hasFormat 5822272.ris.
- aggregation hasFormat 5822272.txt.
- aggregation hasFormat 5822272.xls.
- aggregation hasFormat 5822272.yaml.
- aggregation isPartOf urn:issn:1355-008X.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports".
- aggregation abstract "Ipilimumab is a monoclonal antibody that blocks cytotoxic T-lymphocyte antigen4 (CTLA-4), an inhibitory molecule typically expressed on T cells. Blockade of CTLA-4 induces an overall activation of T cells, including an immune-mediated anti-tumour response. Unfortunately, this broad T cell stimulation also causes immune-related adverse events (irAEs), such as dermatitis, colitis, hepatitis and hypophysitis. Ipilimumab is currently available in Belgium as a second line of treatment for patients with advanced melanoma, and is used at a dose of 3 mg/kg of body weight, although higher doses were previously used (up to 10 mg/kg). We performed a retrospective analysis to identify melanoma patients treated with ipilimumab at the Ghent University Hospital between 2010 and 2013. Data on symptoms, stage and timing of ipilimumab, response and adverse events were collected with a special attention to endocrine disturbances, going from a limited involvement of one endocrine axis to development of a hypophysitis. We identified a total of 39 patients with stage III (No. = 7) or stage IV (No. = 32) melanoma, who received a dose of 3 (No. = 31) or 10 (No. = 8) mg/kg. Six patients developed a severe form of irAEs, including one case of colitis (2 %), one case of sarcoidosis (2 %) and 4 cases (10 %) of hypophysitis. Hypophysitis developed between the second and fourth cycle of ipilimumab administration and was independent of the dose used. We describe four cases of involvement of the pituitary gland during treatment with ipilimumab. When managed with vigilant monitoring and high-dose corticosteroids, the acute symptoms resolve, but lifelong hormone substitution therapy can be necessary. Involvement of the pituitary axes is a severe side effect of treatment with ipilimumab with an urgent need for the correct medical intervention.".
- aggregation authorList BK1452228.
- aggregation endPage "883".
- aggregation issue "3".
- aggregation startPage "878".
- aggregation volume "47".
- aggregation aggregates 5823495.
- aggregation isDescribedBy 5822272.
- aggregation similarTo s12020-014-0199-9.
- aggregation similarTo LU-5822272.